Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

David Gray Biography and Net Worth

SVP, Chief Strategy & New Business Officer of Azenta

Dr. Gray joined the company in 2014 and leads next generation product, technology, and business initiatives as well as corporate strategy. Previously he founded and served as GM of our Automated Cryogenic Solutions business. Prior to joining the company, Dr. Gray held the position of Chief Strategy and New Business Officer at GT Advanced Technologies where he served in various executive management roles and was responsible for global strategy development and execution as well as internal product development. He spent several years as an M&A and strategic advisor to companies in the technology and life science industries.

Dr. Gray has a Bachelors degree in Chemical Engineering from Carnegie Mellon University, Masters and PhD degrees in Chemical Engineering from MIT, and an MBA degree from Stanford University.

What is David C. Gray's net worth?: The estimated net worth of David C. Gray is at least $3.93 million as of August 10th, 2023. Dr. Gray owns 87,919 shares of Azenta stock worth more than $3,925,583 as of November 21st. This net worth approximation does not reflect any other investments that Dr. Gray may own. Learn More about David C. Gray's net worth.
How do I contact David C. Gray?: The corporate mailing address for Dr. Gray and other Azenta executives is 15 Elizabeth Dr, Chelmsford, Massachusetts 01824-4111. Azenta can also be reached via phone at (978) 262-2400 and via email at [email protected]. Learn More on David C. Gray's contact information.
Has David C. Gray been buying or selling shares of Azenta?: David C. Gray has not been actively trading shares of Azenta during the past quarter. Most recently, David C. Gray sold 4,311 shares of the business's stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $57.24, for a transaction totalling $246,761.64. Following the completion of the sale, the insider now directly owns 87,919 shares of the company's stock, valued at $5,032,483.56. Learn More on David C. Gray's trading history.
Who are Azenta's active insiders?: Azenta's insider roster includes Kimberly Crowley (SVP), Linda De Jesus (Insider), and David Gray (SVP, Chief Strategy & New Business Officer). Learn More on Azenta's active insiders.
Are insiders buying or selling shares of Azenta?: During the last year, Azenta insiders bought shares 2 times. They purchased a total of 25,217 shares worth more than $997,067.16. During the last year, insiders at the sold shares 1 times. They sold a total of 1,595 shares worth more than $69,669.60. The most recent insider tranaction occured on November, 18th when CEO John Marotta bought 12,717 shares worth more than $502,067.16. Insiders at Azenta own 1.8% of the company. Learn More about insider trades at Azenta.
Information on this page was last updated on 11/18/2024.

David C. Gray Insider Trading History at Azenta

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2023	Sell	4,311	$57.24	$246,761.64	87,919

David C. Gray Buying and Selling Activity at Azenta

Azenta Company Overview

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Today's Range

Now: $44.65

$43.52

$46.01

50 Day Range

MA: $45.32

$40.37

$49.50

2 Week Range

Now: $44.65

$38.82

$69.16

Volume

1,942,916 shs

Average Volume

510,152 shs

Market Capitalization

$2.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate